Sinopharm Group's CNMDC sees revenue and profit decline in 2024

Sinopharm Group Co. Ltd. (HKEX: 1099) announced the principal financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the year ended December 31, 2024. CNMDC reported revenue of RMB 76.698 billion, a 7.75% decrease compared to the RMB 83.141 billion reported in 2023. Operating profit also saw a substantial decline, falling 53.02% to RMB 1.219 billion. Total comprehensive income attributable to owners of the parent company decreased by 60.88% to RMB 403.336 million. Net cash flow from operating activities showed a significant shift, moving from an inflow of RMB 732.098 million in 2023 to an outflow of RMB 1.356 billion in 2024. As of December 31, 2024, CNMDC's total assets were RMB 61.661 billion, a 6.69% increase year-over-year, and total equity attributable to owners of the parent company was RMB 7.884 billion, up 2.17% from the previous year.